Default company panoramic image
C1607150 c5a3 44b0 af3c 797d517962c1

Eolas Therapeutics, Inc.

Eolas is developing a much safer and more efficacious smoking cessation drug by specifically targeting the addiction motivation pathway.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Carlsbad, CA, USA
  • Currency USD
  • Founded November 2011
  • Employees 3

Company Summary

Eolas Therapeutics is a therapeutic development company with lead programs to treat nicotine and other drug addictions. The healthcare and cost benefits to smoking cessation alone are massive, but current treatments are ineffective. EORA101 is a first-in-class drug that specifically interferes with addiction motivation rather than individual drug signaling pathways. This targeting strategy can yield a much safer and more effective treatment.

Team

  • Default avatar
    Albert Man
    Founder and CEO

    Dr. Man has 10+ years experience in entrepreneurial stage biotech. He has successfully driven several products from concept to commercialization, helped obtain ~$9M in small business grant funding, and has experience running mutlicenter patient studies and FDA regulatory planning. He has a PhD in molecular pathology from UC San Diego, a degree in economics from UC Berkeley, and did his research at the Sanford-Burnham Medical Research Institute.

  • Default avatar
    Paul Kenny
    Founder

    Dr. Kenny is a tenured associate professor at The Scripps Research Institute, Florida. He was the recipient of the prestigious 2010 Jacob P. Waletzky Memorial Award for Innovative Research in Drug Addiction and Alcoholism. Over the last decade, he has made outstanding contributions to the neuropharmacology and molecular study of drug addiction and is considered a thought leader in the field. Dr. Kenny earned his PhD from King’s College London.

  • Default avatar
    Ted Kamenecka
    Founder

    Dr. Kamenecka is an assistant professor at The Scripps Research Institute, Florida. He has extensive industry experience in drug development, and was a medicinal chemist at Merck for 6 years before joining Scripps. He has expertise in medicinal chemistry, design, synthesis, optimization, and evaluation of novel compounds of biological and therapeutic interest. He has a Ph.D. from UC Irvine and post-doc at Memorial Sloan-Kettering Cancer Center.

Previous Investors

  • Default avatar
    none
    Unconfirmed